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Abstract
Autosomal Recessive Spastic Ataxia of Charlevoix-Saguenay (ARSACS) is caused by mutations in the gene SACS, encoding the
520 kDa protein sacsin. Although sacsin’s physiological role is largely unknown, its sequence domains suggest a molecular
chaperone or protein quality control function. Consequences of its loss include neurofilament network abnormalities,
specifically accumulation and bundling of perikaryal and dendritic neurofilaments. To investigate if loss of sacsin affects in-
termediate filaments more generally, the distribution of vimentin was analysed in ARSACS patient fibroblasts and in cells
where sacsin expression was reduced. Abnormal perinuclear accumulation of vimentin filaments, which sometimes had a
cage-like appearance, occurred in sacsin-deficient cells. Mitochondria and other organelles were displaced to the periphery of
vimentin accumulations. Reorganization of the vimentin network occurs in vitro under stress conditions, including when mis-
folded proteins accumulate. In ARSACS patient fibroblasts HSP70, ubiquitin and the autophagy-lysosome pathway proteins
Lamp2 and p62 relocalized to the area of the vimentin accumulation. There was no overall increase in ubiquitinated proteins,
suggesting the ubiquitin–proteasome system was not impaired. There was evidence for alterations in the autophagy–
lysosome pathway. Specifically, in ARSACS HDFs cellular levels of Lamp2 were elevated while levels of p62, which is degraded
in autophagy, were decreased. Moreover, autophagic flux was increased in ARSACS HDFs under starvation conditions.
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These data show that loss of sacsin effects the organization of intermediate filaments in multiple cell types, which impacts
the cellular distribution of other organelles and influences autophagic activity.
Introduction
Autosomal Recessive Spastic Ataxia of Charlevoix-Saguenay
(ARSACS) is a neurodegenerative disease associated with pro-
gressive loss of Purkinje neurons (1,2). It is a childhood onset
condition that is characterized by cerebellar ataxia, pyramidal
spasticity and peripheral neuropathy. At the genetic level,
ARSACS is caused by mutations in the SACS gene (3). This en-
codes the extremely large (4579 amino acid) modular protein
sacsin, which from its N- to C-terminus is composed of a
ubiquitin-like domain that binds to the proteasome (4), three
large sacsin repeat regions that may have an Hsp90-like func-
tion (5,6), a J-domain that binds HSP70 (4,5) and a higher eukary-
otes and prokaryotes nucleotide-binding domain that can
dimerise (7). Based on the presence of these conserved domains,
some of which are present in molecular chaperones and compo-
nents of the ubiquitin–proteasome system, it is a possibility
that sacsin may function in proteostasis.
It is unclear if a molecular chaperone role for sacsin would
be consistent with findings from cellular and mouse models of
ARSACS, where cytoskeletal and mitochondrial abnormalities
have been identified. Specifically, in the Sacs/ mouse we have
shown that loss of sacsin results in abnormal neurofilament ac-
cumulations in the somatodendritic regions of several neuronal
populations as early as 14 days after birth (8). Furthermore, in
cultured hippocampal neurons where sacsin was targeted with
shRNA, and in spinal motor neurons and dorsal root ganglion
(DRG) neurons cultured from Sacs/ mice, a similar redistribu-
tion of neurofilament was observed. These abnormal neurofila-
ment accumulations were demonstrated to contain the
hypo-phosphorylated form of neurofilament heavy chain pro-
tein (NFH) (8). In addition to intermediate filament defects, loss
of sacsin altered mitochondrial morphology, dynamics and dis-
tribution. Mitochondrial length is increased (2,8,9), consistent
with reduced mitochondrial recruitment of the fission factor
dynamin related protein 1 (Drp1) contributing to this phenotype
(9). In agreement with others, we have also demonstrated that
the morphological alterations in mitochondrial networks are ac-
companied by impaired oxidative phosphorylation and in-
creased oxidative stress (2,9,10). Mitochondrial motility was
impaired in motor neurons cultured from Sacs/ mice (8).
Together these data indicate that loss of sacsin causes problems
with both the intermediate filament cytoskeleton and mito-
chondria function, phenotypic aspects that are not mutually ex-
clusive given the importance of the cytoskeleton in regulating
mitochondrial dynamics (11,12).
As we had observed impaired mitochondrial function in
human dermal fibroblasts (HDFs) from ARSACS patients
(2,9,10), we hypothesized that these cells may also exhibit cy-
toskeletal changes. Thus, we investigated the organization of
the vimentin intermediate filament network in HDFs derived
from skin biopsies of ARSACS patients (vimentin being the
major intermediate filament protein in fibroblasts). In a pro-
portion of ARSACS cells, intermediate filaments were bundled
and collapsed as a cage-like structure around the microtubule
organizing centre (MTOC) rather than radiating from the nu-
cleus towards the plasma membrane, as in control cells. These
vimentin structures were reminiscent of the ‘cage’ of the
vimentin intermediate filaments that surround aggresomes.
Aggresomes form when misfolded protein aggregates are traf-
ficked in a retrograde manner to the MTOC, where they accu-
mulate prior to clearance by the autophagy–lysosome
machinery (13,14). Thus, we investigated the distribution and
function of the proteostasis machinery in ARSACS fibroblasts,
observing components of the cellular proteostasis machinery
relocalized within the accumulations of vimentin. Moreover,
aspects of the phenotype were recapitulated in primary
neurons from the Sacs/ mouse. In combination, our data
show that loss of sacsin impacts on intermediate fila-
ment organization leading to changes in the cellular distribu-
tion of proteostasis system components and altered
autophagy.
Results
The vimentin intermediate filament cytoskeleton is
disrupted in ARSACS patient fibroblasts
We primarily report on ARSACS HDF lines from four patients that
are compound heterozygous (p.Q4054* & c.2094-2A>C; p.R2002fs
& p.Q4054*; p.F2780C & p.S3892*; p.K1715* & p.R4331Q) and one pa-
tient that is homozygous (p.2801delQ) (Supplementary Material,
Fig. S1A). Cell lines from two further compound heterozygous pa-
tients, sharing two variants in cis on one allele (p.R3636Q:p.P3652T)
and a different frameshift on the other allele (p.L3745Rfs or
p.C72Cfs) (15), plus two patients homozygous for the c.8844delT
mutation, the major founder mutation in Que´bec, were also inves-
tigated (Supplementary Material, Figs S1C and D). Using an anti-
body directed to the C-terminus of sacsin, immunoblot showed
that levels of the protein were similar in control HDFs and the HDF
line with the p.2801delQ mutation. Some sacsin was also detected
in HDFs from the ARSACS patient with the p.R3636Q:p.P3652T:p.
C72Cfs mutations (Supplementary Material, Fig. S1). Sacsin was
not conclusively detected in cell lines from patients with the other
mutations investigated.
Confocal imaging revealed that a large proportion of cells in all
of the ARSACS patients HDF lines investigated had a grossly ab-
normal vimentin cytoskeleton. In contrast to wild-type control
cells, where vimentin was distributed throughout the cytoplasm,
vimentin filaments were bundled in perinuclear accumulations in
patient cells (Fig. 1A and B and Supplementary Material, Fig. S2).
This phenotype was highly penetrant with 79.66 1.9% of ARSACS
HDFs (Fig. 1B and Supplementary Material, Fig. S2A) having a
disorganized vimentin network, relative to just 8.561.2% of con-
trol cells. Vimentin filaments were also disrupted in the ARSACS
lines that still have detectable sacsin protein, with sacsin being
localized to the area of filament accumulation, rather than being
distributed throughout the cytoplasm, as in wild-type control cells
(Fig. 1C).
Transmission electron microscopy (TEM) revealed that in
ARSACS HDFs cytoplasmic organelles were localized peripher-
ally to a perinuclear region of uniform electron density (Fig. 1D).
Higher-magnification imaging indicated this region contained
significant amounts of 10 nm filamentous material, consistent
with the size of intermediate filaments. The region of filamen-
tous material accumulation frequently contained vesicular
structures and vacuoles.
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Figure 1. Abnormal accumulations of vimentin intermediate filament in ARSACS patient HDFs. (A) Representative confocal images of five ARSACS patient HDFs and a
wild-type (WT) control HDF line (further patient and control lines are shown in Supplementary Material, Fig. S2) that were stained for mitochondria (MitoTracker) and
immunolabelled for vimentin. Cells were also stained with DAPI to detect nuclei. Arrows indicate areas of abnormal perinuclear vimentin accumulation. Scale bars ¼
10lm. (B) The percentage of cells with a collapsed vimentin network was then quantified for each cell line. This was done blind to experimental status with >120 cells
scored per cell line. Results are expressed as mean6SEM for each control and patient cell line. (C) Representative confocal images of HDFs from a homozygous ARSACS
patient with the mutation p.2801delQ and a wild-type control line. HDFs were processed for immunofluorescent detection of sacsin and vimentin, and were counter-
stained with DAPI for nuclei. Localization of sacsin to the area of perinuclear vimentin accumulation is indicated by an arrow. Red dotted line indicates the edge of the
cell. Scale bars ¼ 10lm. (D) Representative TEM of a HDF cell from a wild-type control and ARSACS patient (p.R2002fs & p.Q4054*). Boxes delineated by white lines indi-
cate position of zoomed images shown in panels I and II. Red dotted line indicates the approximate boundary of the area of accumulation of filamentous material.
Examples of filaments are indicated with arrows. Scale bar ¼ 5 lm.
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Sacsin knockdown disrupts vimentin intermediate
filament organization in wild-type cells
To further confirm that loss of functional sacsin results in al-
tered vimentin organization, siRNA-mediated knockdown was
used to deplete sacsin in wild-type HDFs, using previously vali-
dated siRNAs (4,9). A significant increase (P< 0.01) in the per-
centage of sacsin knockdown HDFs that exhibited a perinuclear
accumulation of vimentin was observed relative to controls,
with vimentin bundles visible in some cells (Fig. 2A). We also
made a HEK293 sacsin knockout line using CRISPR/Cas9 genome
editing. These cells did not express detectable levels of sacsin
and also exhibited perinuclear collapse of the vimentin network
(Fig. 2B and C). In these cells, we were able to rescue the vimen-
tin phenotype by transfection of a plasmid for expression of
full-length sacsin-GFP (Fig. 2B and C).
Vimentin accumulates around the MTOC and disrupts
the distribution of organelles in ARSACS patient cells
As cytoskeletal elements are interlinked we used confocal anal-
yses to investigate if the actin filament and microtubule net-
works were disrupted in ARSACS HDFs. We observed no gross
abnormalities in actin microfilament (not shown) or microtu-
bule organization. However, labelling with anti-tubulin did re-
veal that the abnormal accumulations of vimentin formed in
close proximity to the MTOC (Fig. 3A and Supplementary
Material, Fig. S3A).
Collapse of the vimentin network would be expected to have
consequences for the distribution of organelles, as the cytoskel-
eton organizes the intracellular space. Indeed, confocal imaging
showed displacement of mitochondria to areas peripheral to
the abnormal accumulations of vimentin in ARSACS patient
SACS siRNAA
M
er
ge
Vi
m
en
tin
Non-Targeting siRNA
M
ito
D
s 
re
d
Sacs-/-  Sacs-/-+ Sacsin-GFP
M
er
ge
Control
Vi
m
en
tin
B C
 
Sacsin
β-actin
520 kDa
42 kDa
0
10
20
30
40
50
60
70
%
 o
f v
im
en
tin
 b
un
dl
es
 
80
90
100
Control 
Sacs-/-
Sacs-/-
Sacsin-GFP
+
D
Figure 2. Abnormal accumulations of vimentin intermediate filament in sacsin knockdown cells. (A) Representative confocal images of wild-type HDFs cotransfected
with mitoDSRed and either a non-targeting siRNA or siRNA targeting sacsin (SACS). 48 h after transfection, cells were processed for immunofluorescent detection of
vimentin and counterstained with DAPI for nuclei. Scale bars¼ 10 mm. (B) Representative confocal images of CRISPR generated SACS/ HEK293 cells and SACS/
HEK293 transfected with a plasmid for expression of full-length sacsin-GFP. Cells were processed for immunofluorescent detection of vimentin and counterstained
with DAPI. (C) The percentage of cells with a collapsed vimentin network was then quantified for each condition. This was done blind to experimental status with >45
cells scored per condition. Results are expressed as mean6SEM. (D) Sacsin immunoblot of total lysates from control and SACS/ HEK293 cells. b-actin was used as a
loading control.
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cells (Fig. 1A). Disruption of the intermediate filament cytoskele-
ton has also been reported to interfere with Golgi organization
(16,17). Confocal imaging of HDFs immunolabelled with the
Golgi protein, GS28, revealed a fragmented Golgi stack, with cis-
ternae displaced around an area of cytoplasm where
mitochondria where also absent (Fig. 3B and Supplementary
Material, Fig. S3B). With available antibodies, it was not possible
to double-label cells with antibodies to vimentin and GS28, but
it is likely that fragmented Golgi was displaced around areas of
vimentin accumulation. Distribution of the endosome marker,
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Figure 3. ARSACS HDFs show characteristics of aggresome formations, including accumulation of vimentin around the MTOC and Golgi fragmentation. (A,B)
Representative confocal images of two ARSACS patient HDFs lines (heterozygous mutations c.2094-2A>G/Q4054* and the homozygous mutation p.2801delQ) and a
WT control (further patient and control lines are shown in Supplementary Material, Fig. S3). Cell were stained with MitoTracker before being processed for immunoflu-
orescent detection of (A) vimentin and b-tubulin, or (B) GS28, a membrane protein of the cis-Golgi. Cells were counterstained with DAPI for nuclei. White boxes are
shown as zoomed images in the right-hand panels. Arrows indicate areas of mitochondrial network disruption. Scale bars¼10lm.
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Figure 4. Components of the cellular proteostasis machinery localise to the vimentin cage that forms in ARSACS patient HDFs. (A,B) Representative confocal images of
two ARSACS patient HDFs lines (heterozygous mutations c.2094-2A>G/p.Q4054* and the homozygous mutation p.2801delQ) and a WT control (further patient and con-
trol lines are shown in Supplementary Material, Fig. S4). Cells were immunolabelled for (A) HSP70 and vimentin, or (B) ubiquitin and vimentin, as well as mitochondria
(MitoTracker) and nuclei (DAPI). White arrows indicate perinuclear accumulation of HSP70 or ubiquitin. White boxes in merged panels are shown zoomed. Scale
bars¼10lm. (C,D) The incidence of cells with perinulear localization of (C) HSP70 or (D) ubiquitin was quantified. For ubiquitin, quantification was performed in cells
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EEA1, was also altered in ARSACS HDFs. Relative to wild-type
controls, endosomes were less evenly distributed throughout
the cell (Supplementary Material, Fig. S3C), distributing with
displaced mitochondria.
Components of the cellular proteostasis machinery
relocalize to the region of abnormal vimentin
accumulation in ARSACS patient cells
The combination of perinuclear accumulation of vimentin
around the MTOC, disrupted mitochondrial network organ-
ization and Golgi fragmentation have been linked to aggresome
formation in cultured cells. Aggresomes are juxtanuclear accu-
mulations of misfolded proteins that form through a regulated
process when cellular protein-degradation systems become
overwhelmed, a common phenomenon in neurodegenerative
disorders (18–20). To look for evidence of disrupted proteostasis
in ARSACS HDFs, cells were immunolabelled with an antibody
that detects both constitutive (HSPA8) and inducible (HSPA1)
isoforms of the molecular chaperone HSP70, which interacts
with misfolded proteins and can localize to aggresomes (21,22).
In control HDFs, HSP70 labelling was distributed throughout the
cytoplasm, while in patient cells HSP70 was frequently enriched
in the region with abnormal accumulation of vimentin (Fig. 4A
and Supplementary Material, Fig. S4A). Confocal z-stack images
indicated HSP70 was surrounded by a ‘cage-like’ bundle of
vimentin, with some HSP70 also interspersed within the abnor-
mal accumulation of vimentin. HSP70 labelling appeared re-
duced in other regions of the cytoplasm. This relocalization of
HSP70 in ARSACS HDFs was not accompanied by an increase in
overall cellular levels of HSPA8 or expression of HSPA1, as deter-
mined by immunoblot (Fig. 4E and F).
Misfolded proteins that cannot be refolded by chaperones
are normally targeted for degradation by ubiquitination. Thus,
we next compared localization of ubiquitin in wild-type and
ARSACS HDFs. Similar to HSP70, we observed ARSACS HDFs
where ubiquitin labelling was redistributed to the area of
vimentin accumulations, rather than being dispersed as in con-
trol cells (Fig. 4B). The percentage of cells with this ubiquitin
phenotype (14 6 3%) was low relative to the those that
relocalized HSP70 (85 6 2%) and there was no significant change
in level of ubiquitinated proteins in ARSACS HDFs relative to
wild-type HDFs. Immunoblots indicated this was the case, both
in cells cultured under normal conditions and in cells treated
with MG132 to inhibit proteasome activity (Fig. 4G). Together
these data indicate that although proteostasis-linked proteins
are relocalized in response to loss of sacsin, the ubiquitin–pro-
teasome system does not appear compromised.
Lamp2 and other components of the autophagy–
lysosome pathway are relocalized to the region of
abnormal vimentin accumulation in ARSACS patient
cells and have altered cellular levels
Separate to aggresome formation, vimentin deficiency is associ-
ated with juxtanuclear accumulation of lysosomes (23). To ascer-
tain if lysosome localization was altered in ARSACS HDFs, control
and patient cells were immunolabelled for vimentin and
lysosomal-associated membrane protein 2 (Lamp2). Lamp2 was
distributed throughout the cytoplasm in control HDFs. In a signif-
icant (P< 0.01) percentage of patient cells Lamp2 positive puncta
were clustered within the region of vimentin accumulation, here
it was both interspersed with the vimentin and localized within
the vimentin ‘cage’ (Fig. 5A and C, Supplementary Material, Fig.
S5). Similar to Lamp2, the ubiquitin-binding autophagic adaptor
protein p62 (also known as SQSTM1), which is required for auto-
phagic clearance of ubiquitinated proteins (24,25), was also
relocalized within the vimentin cage (Fig. 5B and D). Immunoblot
showed a small, but statistically significant, increase in Lamp2
levels in ARSACS HDF relative to controls (1.19-fold increase,
P< 0.05) (Fig. 5E and F). Contrastingly, levels of p62 were reduced
in ARSACS HDFs relative to controls (0.5-fold decrease, P< 0.05).
This was of particular interest as p62 has been identified as one
of the specific substrates that is degraded through the
autophagy–lysosome pathway (26–28).
Autophagic flux is altered in ARSACS patient cells
We next considered whether autophagosomes accumulated in
the region of the vimentin cage. Ultrastructural analyses of
ARSACS patient cells reveals accumulation of filamentous ma-
terial are interspersed with components of the autophagy–lyso-
some system, including autophagosomes (Fig. 6A). The
presence of autophagosomes within the filament accumula-
tions and the immunolabelling of lysosomes within the vimen-
tin ‘cage’ (Fig. 5A) are consistent with autophagic clearance
happening at this location.
To ascertain if there was increased activation of the
autophagy-lysosome pathway in ARSACS HDFs, the number of
LC3 positive puncta were quantified from confocal images of
immuolabelled patient and control cells (Fig. 6B and C). The
number of LC3 positive puncta was not significantly different
between ARSACS HDFs and control cells under basal conditions.
In contrast, induction of autophagy by nutrient starvation only
resulted in an increase in LC3 positive puncta in control cells
(P< 0.001). This indicates that either LC3 positive puncta are not
forming in response to nutrient starvation in ARSACS HDFs or
their turnover is increased. Since generation of LC3-II from its
precursor, LC3-I, correlates with autophagosome formation, lev-
els of LC3-I and LC3-II were assessed by immunoblotting (Fig.
6D and E). Under basal conditions, levels of LC3-I were similar in
ARSACS patient and controls, but LC3-II was not detectable at
quantifiable levels. When autophagy was induced by nutrient
starvation LC3-II levels increased in starved cells, and impor-
tantly, significantly more LC3-II accumulated in controls than
patient cells. To understand why less LC3-II accumulated in
ARSACS HDFs relative to controls, we inhibited lysosomal deg-
radation using bafilomycin A. In nutrient starved cells treated
with bafilomycin A, levels of LC3-II were not significantly differ-
ent between ARSACS and control HDFs. The same result was ob-
served when autophagy was inhibited with 3-Methyladenine
(Fig. 6D and E). These data suggest that LC3 is more rapidly de-
graded and that autophagic flux is increased under conditions
that induce autophagy in ARSACS HDFs.
cultured under control conditions (vehicle only) or treated with the proteasome inhibitor MG132 for 3 h. Results are expressed as mean6SEM. (E) Immunoblot analysis
of total cell lysates from five ARSACS patient and five WT control HDFs probed with an anti-HSP70 antibody. GAPDH was used as a loading control. (F) Densitometric
analyses were performed and mean relative HSP70 protein levels calculated for the five WT and five patient cell lines. Data were normalized to GAPDH. (G)
Immunoblot analysis of total cell lysates from five ARSACS patient and five WT control HDFs cultured for 3 h in the presence of MG132 or vehicle only control, probed
with an anti-ubiquitin antibody. GAPDH was used as a loading control.
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Figure 5. Components of the autophagy–lysosome pathway localise to the vimentin cage that forms in ARSACS patient HDFs. (A,B) Representative confocal images of
two ARSACS patient HDFs lines (heterozygous mutations c.2094-2A>G/p.Q4054* and the homozygous mutation p.2801delQ) and a WT control (further patient and con-
trol lines are shown in Supplementary Material, Fig. S5). Cells were stained for mitochondria (MitoTracker) and then immunolabelled for (A) LAMP-2 (lysosome-
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Neurofilament bundling, organelle displacement and
relocalization of ubiquitin occurs in Sacs/ primary
neurons
We previously reported abnormal bundling of neurofilaments in
primary spinal motor and sensory neurons cultured from
Sacs/ mouse embryos (8). In 4-week-old dissociated spinal
cord cultures, bundling of neurofilaments was detected in the
soma of Sacs/ motor (85.464.9%) and sensory neurons
(73.56 8.5%) by immunolabelling with antibody against the high
molecular weight neurofilament protein (NFH), as previously
described (8) (Fig. 7A). In motor neurons, the normal neurofila-
ment network courses through the cell body into the dendritic
processes, whereas DRG sensory neurons lack dendrites. In
Sacs/ motor neurons, neurofilaments coalesce into linear bun-
dles, whereas in DRG neurons, they can form a juxtanuclear ball
reminiscent of vimentin bundles in fibroblasts. Peripheral dis-
placement of the nucleus was particularly visible in DRG sen-
sory neurons with a collapsed neurofilament network (Fig. 7B
and C). Mitochondria were excluded from the region of the neu-
rofilament accumulations (Fig. 7D). Moreover, ubiquitin had a
more perinuclear distribution in Sacs/ neurons compared with
controls (Fig. 7G and H); this was statistically significant in both
motor neurons (P< 0.05) and DRG sensory neurons (P< 0.05)
(Fig. 7E and H). In contrast to ARSACS patient HDFs, there was
no significant redistribution of the autophagy–lysosomal pro-
teins Lamp2 or p62 in Sacs/ neurons (not shown).
Discussion
Here, we present evidence that organization of the vimentin cy-
toskeleton is dramatically altered in ARSACS HDFs with a range
of sacsin mutations and in cellular models where sacsin has
been depleted. This is in agreement with our previous findings
that abnormal accumulations of neurofilament occur in Sacs/
primary neurons (8). Importantly, these data indicate that loss
of sacsin impacts on more than one type of intermediate fila-
ment, suggesting sacsin function may be broadly required for
normal intermediate filament organization.
Cells lacking functional sacsin also exhibit abnormalities in or-
ganelle distribution, such as fragmentation of the Golgi in ARSACS
HDFs and asymmetrical positioning of nuclei in Sacs/ neurons.
This is consistent with intermediate filaments playing a role in in-
tracellular organelle distribution (29,30) and may be relevant to the
pathogenesis of ARSACS. We have previously shown recruitment
of the fission factor Drp1 to mitochondria is impaired in sacsin
null cells, proposing this partly explains the alterations in mito-
chondrial dynamics and function observed in cellular models of
ARSACS (9). Displacement of mitochondria at the periphery of
vimentin accumulations in ARSACS HDFs suggests that disrupted
organelle distribution may also impact mitochondrial network
organization and potentially function. Interestingly, in HDFs tran-
siently transfected with siRNA targeting sacsin, there was not an
obvious alteration in mitochondrial localization compared with
that which we observed in ARSACS patient HDFs. We speculate
that this difference is likely due to partial knockdown of sacsin
and/or that the time after transfection (48 h) was not sufficient to
induce this aspect of the loss of sacsin phenotype.
Collapse of the vimentin network around the MTOC occurs
when mechanisms regulating intermediate filaments are dis-
rupted and as well as in response to stress conditions such as
the accumulation of misfolded protein aggregates (18,23,31). We
did not see any direct evidence for accumulation of protein ag-
gregates in ARSACS patient HDFs by TEM, or find the UPS to be
compromised (i.e. no accumulation of ubiquitinated proteins).
This suggests that the altered vimentin network in sacsin defi-
cient cells is not the result of a problem with clearance of ubiq-
uitinated proteins. Although ubiquitinated proteins did not
accumulate in ARSACS HDFs, multiple components of the pro-
teostasis machinery were relocalized to the pericentriolar re-
gion of vimentin accumulation. These included HSP70 and
components of the autophagy–lysosome machinery.
Interestingly, levels of p62 were decreased in ARSACS fibro-
blasts, while Lamp2 levels were elevated. p62 is degraded by
autophagy and Lamp2 promotes fusion of autophagosomes
with lysosomes (28,32). We analysed LC3 levels to determine if
autophagy was activated in ARSACS HDFs, demonstrating auto-
phagic flux was increased under conditions of nutrient starva-
tion. These data suggest that the relocalization of lysosomes in
ARSACS HDFs is associated with functional changes in the
autophagy–lysosome pathways. This would be in agreement
with juxtanuclear clustering of lysosomes being associated with
increased autophagosome–lysosome fusion rates (33,34).
The phenotypes observed in ARSACS HDF and primary neu-
rons from the Sacs/ mouse only partially recapitulated each
other. For example, while vimentin is organized as a ‘cage’ in
some ARSACS HDFs, neurofilaments form bundles, especially in
dendrites, reflecting a difference in the organization of the
cytoarchitecture. Moreover, we did not see any evidence for
relocalization of components of the autophagy–lysosomes path-
way in primary neurons from the Sacs/ mouse, but did see
perinuclear accumulation of ubiquitin in neurons from the
Sacs/ mouse. This ubiquitin staining may represent ubiquiti-
nated proteins that are destined for removal by the autophagy–
lysosome pathway, although we did not see any evidence for
relocalization of lysosomes or autophagy proteins in primary
neurons. These differences between neurons and fibroblasts
may reflect cell-specific aspects of cytoskeleton or proteostasis
regulation. Indeed, previous reports show that common in-
ducers of autophagy in non-neuronal cells fail to stimulate
autophagy in primary neurons, highlighting that autophagy in
neurons is regulated by mechanisms that may differ from those
in non-neuronal cells (35,36).
The sequence of events that lead to neuronal cell death in
ARSACS is unknown but most of the evidence supports that the
cytoskeletal disorganization is an early phenomenon (8).
Altered proteostasis, mitochondrial dysfunction and cytoskele-
tal abnormalities are all features observed in other neurodegen-
erative diseases. These components of molecular pathology
frequently occur in combination with multiple complex links
between them. For ARSACS, based on the presence of domains
linking to molecular chaperones and the UPS it would be rea-
sonable to speculate sacsin has a role in protein quality control,
most likely for a specific client or family of client proteins. If
this is the case it would suggest that loss of sacsin function
would result in altered levels or function of these clients at an
associated membrane protein 2) and vimentin, or (B) p62/SQSTM1. Cells were also stained with DAPI to detect nuclei. White boxes in the merged panels are shown
zoomed in the right-hand panels. Arrows indicate areas of LAMP-2 or p62 accumulation. Scale bars¼10lm. (C,D) The incidence of cells with perinulear localization of
(C) Lamp2 or (D) p62 was quantified. (E,F) Immunoblot of total cell lysates from five ARSACS patient and five WT control HDFs probed with an anti-Lamp2 antibody and
subsequent densitometric analyses. (G,H) Immunoblot of total cell lysates from five ARSACS patient and five WT control HDFs probed with an anti-p62 antibody and
subsequent densitometric analyses. Data were normalised to GAPDH.
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Figure 6. Autopahgic Flux is increased in ARSACS patient HDFs upon nutrient starvation. (A) Representative EM image of autophagosomes (arrowheads) in the area of
intermediate filament (arrows) accumulation in an ARSACS HDF. Scale bar ¼ 1 lm. (B) Representative confocal images of two ARSACS patient HDFs lines (heterozygous
mutations c.2094-2A>G/p.Q4054* and the homozygous mutation p.2801delQ) and a WT control immunolabelled for endogenous LC3. Scale bar ¼ 10lm. (C)
Quantification of the number of LC3 puncta in ARSACS and control HDF lines under basal conditions and after induction of autophagy by nutrient starvation. Puncta
were quantified in 12 cells per line/treatment. Results from five control and five patient cell lines were combined to give an overall mean6SEM, ***P<0.001. (D)
Immunoblot analysis of total cell lysates from ARSACS patient and WT control HDFs probed with an LC3 antibody to detect LC3-I and LC3-II. Cell lysates were collected
from untreated cells, nutrient starved cells, and cells that were nutrient starved and treated with either bafilomycin A or 3-Methyladenine (3-MA). Actin was used as a
loading control. (E) Densitometric analyses were performed and mean LC3-I and LC3-II levels relative to actin were calculated for each treatment in control and
ARSACS HDFs (n¼ 4).
3139Human Molecular Genetics, 2017, Vol. 26, No. 16 |
MN
0
20
40
60
80
100
120
WT KO
M
ot
or
 n
eu
ro
ns
 (%
)
*
Diffuse
Perinuclear
E F
H
W
T
 S
ac
s 
K
O
MN
UbiquitinTOM20 Merge
*
A B
r1
r2
WT  
r1
r2
Sacs KO  
M
N
 S
N
ZoomWT  Sacs KO  
ZoomWT  Sacs KO  
C
D
M
N
 S
N
WT Sacs KO
Normal
Eccentric
S
en
so
ry
 n
eu
ro
ns
 (%
)
0
20
40
60
80
100
120 *
WT KO
***
W
T
 S
ac
s 
K
O
SN
UbiquitinTOM20 Merge
G
*
SN
0
20
40
60
80
100
120
WT KOS
en
so
ry
 n
eu
ro
ns
 (%
) Diffuse
Perinuclear
Figure 7. Primary neurons from the Sacs/ mouse have abnormal neurofilament organization, altered cellular architecture and abnormal ubiquitin localization. (A)
Representative maximum intensity projections of confocal Z-stacks of primary neurons from 4-week-old dorsal root ganglia and spinal cord culture. Motor (MN) and
sensory neurons (SN) from Sacs/ (Sacs KO) or WT mice were immunolabelled for NFH. Arrows indicate bundled NFH intermediate filaments. (B) Nuclear positioning
in DRG sensory neurons revealed by DAPI (blue) staining for the nucleus and immunostaining for tubulin (red) to identify the soma in the Sacs/ sensory neuron. (C)
3140 | Human Molecular Genetics, 2017, Vol. 26, No. 16
early stage in the molecular pathogenesis of the disease. Our
data may suggest that these clients will be linked to proteins in-
volved in regulation of intermediate filaments or could even be
intermediate filament proteins.
In conclusion, this study shows that loss of sacsin effects
organization of intermediate filament networks with conse-
quences for intracellular architecture. In fibroblasts, these include
repositioning of components of the autophagy–lysosome path-
way and subsequent alterations of autophagic activity.
Materials and Methods
Cell culture and sacsin knockdown
ARSACS patient fibroblasts were a gift from Dr Sascha Vermeer
at Radboud University Nijmegen Medical Centre (Nijmegen, The
Netherlands) and Dr Paola Giunti at UCL Institute of Neurology
(London, UK). The cells were collected as part of a project ap-
proved by the Medical Ethics Committee of the Radboud
University (CMO-nr 2014/155), and Giunti has ethical approval
for dermal fibroblast collection through a European integrated
project on spinocerebellar ataxias (REC Ref - 04/Q0505/21).
Written informed consent to participate in this study was ob-
tained from all patients. Control and ARSACS HDF lines used in
this work were not closely age or sex matched, but were all be-
tween passage 3 and 8. HDFs were cultured in Dulbecco’s
Minimum Eagle Medium (DMEM) supplemented with 10% foetal
bovine serum (FBS) and 50 U/ml penicillin and 50 lg ml1 strep-
tomycin (final concentration in media 1%). All cells were kept in
a constant humidified atmosphere of 5% CO2 at 37C. Cell cul-
ture reagents were from Life Technologies (Paisley, UK).
SH-SY5Y cells were from the American Type Culture
Collection and were grown in DMEM at a 1:1 ratio with Ham’s
F12 medium. Cells were maintained in medium supplemented
with 10% heat-inactivated FBS containing 100 U ml1 penicillin
and 100 mg ml1 streptomycin.
For sacsin knockdown, a combination of three previously
validated siRNAs targeting exons 7 (sense: GGAUGAUCCU
CUGAAGGUC), 8 (sense: GCGGCCGAAUUCUAUAAAG) and 10
(sense: CGUAAGAUUUCUAGAUGAC) of SACS were used (2,4).
These siRNAs were at a concentration of 10 nM each and were
transfected in combination using Lipofectamine 3000
(ThermoFisher Scientific, UK), according to the manufacturer’s
instructions. A negative control siRNA that has no significant
sequence similarity to human gene sequences was used as a
control at a concentration of 30 nM.
Generation of CRISPR/Cas9 SACS/ Flp-In T-REx HEK293 cells
was performed following the manufacturers protocol for the sac-
sin double nickase plasmid (SantaCruz Biotechnology, cat. no. sc-
404592-NIC). For inhibition of the proteasome MG132 was added
to cells at a final concentration of 10 mm for 3 h. For inhibition of
autophagy, Bafilomycin was added to cells at a concentration of
100 nm for 3 h and 3-MA at a concentration of 5 mM for 3 h.
Sacs/ primary neurons were cultured from the Sacs/
mouse as described previously (2,8).
Immunofluorescent detection and staining
Immunofluorescent labelling was as described previously (2). In
brief, cells cultured on glass coverslips were fixed with 4% formal-
dehyde for 15 min and then permeablized for 5 min with 0.2%
Triton-X 100. Cells were incubated with primary antibodies for 2 h
in 0.02% Triton-X100, 1% bovine serum albumin (BSA) and 10% nor-
mal goat serum, prior to washing and incubation with fluores-
cently labelled secondary antibodies [Alexa Fluor 488-conjugated
goat anti-rabbit or anti-mouse, Alexa Fluor 543 conjugated goat
anti-mouse or anti-rabbit, or Alexa Fluor 647-conjugated goat anti-
mouse or anti-rabbit (ThermoFisher Scientific)]. Cells were then
counterstained with DAPI and coverslips mounted for microscopy.
Primary antibodies were used at the following titres; 1:100 for rab-
bit monoclonal anti-vimentin (Abcam, UK), 1:100 for mouse mono-
clonal anti-vimentin (Abcam), 1:100 for rabbit monoclonal anti-
sacsin (Abcam), 1:500 for mouse monoclonal anti-GS28 (Enzo Life
Sciences, UK), 1:100 for mouse monoclonal anti-EEA1 (BD
Biosciences, UK), 1:100 for mouse monoclonal anti-HSP70 (Sigma,
Poole, UK), 1:100 for rabbit polyclonal anti-ubiquitin (Abcam), 1:100
for mouse monoclonal anti-Lamp2 (Santa Cruz, USA), 1:100 for
mouse monoclonal anti-p62 (Abcam) and 1:100 for rabbit poly-
clonal anti-LC3 (Abcam). For staining of mitochondria with
MitoTracker (ThermoFisher Scientific) the stock solution was di-
luted to a concentration of 100 nM in cell culture media prior to ad-
dition to cells for 30 min at 37C in 5% CO2 atmosphere. After the
incubation period, cells were washed twice in cell culture media
prior to live imaging or fixation. Confocal microscopy was per-
formed using a LSM510 or an LSM880 (Zeiss) with a 63 objective.
Quantification of incidence of cells with perinuclear localization of
HSP70, ubiquitin, Lamp2 and p62 was performed blind to experi-
mental status. Incidence of LC3 punctae were quantified from con-
focal Z-stacks using a combination of the Surpass module and
MeasurementPro modules of Imaris (Imaris 7.6.1 Bitplane,
Concord, USA). Surface rendered 3D images were generated, with
thresholding for punctae size and intensity consistent between im-
ages and experimental conditions.
Immunoblotting
Proteins were size-fractionated using precast 4–12% gradient
NuPAGE Bis-Tris gels (Life Technologies) and transferred to ni-
trocellulose membranes (Whatman). Membranes were blocked
in either 5% (w/v) non-fat milk powder or 5% (w/v) BSA before
probing with the specified antibodies. Primary antibodies were
used at the following titres; 1:1600 for rabbit monoclonal anti-
sacsin (Abcam), 1:5000 for mouse monoclonal anti-HSP70
(Sigma) 1:5000 for mouse monoclonal anti-Lamp2 (Santa Cruz),
1:3000 for rabbit polyclonal anti LC3 (Abcam) 1:10 000 for mouse
monoclonal anti-b-actin (Sigma), 1:5000 for rabbit polyclonal
anti-GAPDH (Abcam), 1:1000 for mouse monoclonal anti-p62
(Abcam), and 1:3000 for rabbit polyclonal anti-LC3 (company).
Immunoreactive products were visualized and quantified, after
labelling with species-specific infrared secondary antibodies
(1:5000, LI-COR Biosciences, UK), using the Odyssey imaging
Quantification of the percentage of sensory neuron with eccentric nuclear localization. Eccentric localization of nucleus was determined by the ratio of r1:r2, where r1
is the longest and r2 is the shortest distance between the nuclear membrane and the closest plasma membrane. Cells where r1/r2 was 1.1 (10% deviation from a
centrally positioned nucleus) were scored as having an eccentric nuclear localization (D) Representative confocal images of motor (MN) and sensory neurons (SN) from
Sacs/ (Sacs KO) or WT mice were immunolabelled for Tom20. Arrows indicate areas where mitochondria were absent. (E) Representative confocal images of motor
neurons from Sacs/ (Sacs KO) or WT mice immunolabelled for ubiquitin. (F) Quantification of the number of motor neurons (MN) showing a perinuclear localization
of ubiquitin. (G) Representative confocal images of sensory neurons from Sacs/ (Sacs KO) or WT mice immunolabelled for ubiquitin. (HG Quantification of the number
of sensory neurons (SN) showing a perinuclear localization of ubiquitin. Arrows show areas of ubiquitin accumulation. A white asterisk indicates the location of a glial
cell. Scale bars¼10 mm. Error bars are6SD, *P<0.05. N¼between 30 and 70 neurons per experiment.
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system (LI-COR). Apparent molecular masses were estimated
using the Novex Sharp Pre-stained Protein Standard (Life
Technologies) or HiMark Pre-stained Protein Standard (Life
Technologies) and the band sizing application in Odyssey soft-
ware (LI-COR Biosciences). Images of the immunoblots were
also quantified using the Odyssey software.
Transmission electron microscopy
Cells were grown on glass or Thermanox cover-slips and fixed
overnight in cold (4C) Karnovky’s fixative (2% paraformaldehyde
and 2.5% glutaraldehyde in 0.08M cacodylate buffer). They were
then washed three times in phosphate buffer and osmicated with
1% osmium tetroxide in ddH2O for 1 h. Samples were then
washed 310 min in ddH2O and dehydrated with a series of alco-
hols: 30, 50, 70, 90, 3100% and 2 propylene oxide (at least
20 min in each). They were infiltrated with 50% propylene oxide:
50% araldite resin overnight and with several changes of 100%
resin the next day. Resin blocks were cured at 60C overnight.
Sectioning was done using a Leica Ultracut UCT microtome.
Sections were counter-stained Reynold’s lead citrate and were
viewed on a JEOL 1010 TEM (JEOLUSA, USA).
Statistical analyses
All data are expressed as means6SEM, unless otherwise stated.
Statistical significances were determined using Mann–Whitney
U tests or unpaired Student’s t-tests as appropriate.
Supplementary Material
Supplementary Material is available at HMG online.
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